medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2007, Number 2

<< Back

Ann Hepatol 2007; 6 (2)

In vitro study on the mechanisms of action of a novel phytotherapeutic compound against human hepatoma cells

Marotta F, Harada M, Khean-Lee G, Lorenzetti A, Marandola P, Minelli E

Language: English
References: 35
Page: 111-116
PDF size: 67.29 Kb.


Text Extraction

HepG2 human hepatoma cells were incubated for 24 or 48 h with various concentrations of YHK solution. After 24 h incubation, cell proliferation and cytotoxicity were determined by 3-(4,5-dimethylthiazol-2- yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTT) assay. Cytotoxicity or necrosis was expressed as lactate dehydrogenase (LDH) release. After exponential growth phase HepG2 cells were treated with different doses of YHK and apoptosis was assessed by using an Annexin V-FITC kit. Further, oxidative stress was measured by dichlorofluorescein-diacetate (DCFH-DA) assay. As compared to control, YHK-treated cultures showed a significant time-course decrease of the proliferation rate of HepG2 cell growth (p ‹ 0.01). This is likely to be due to an enhanced cytotoxicity (MTT and LDH tests) (p ‹ 0.001). On the other hand, YHK showed in vitro to significantly enhance the oxidative stress of HepG2 cell (p ‹ 0.01) while also markedly increasing apoptosis at 72 h with cells G2/M phase arrest (p ‹, 0.01). These data suggest that YHK seem to modulate the extrinsic and intrinsic regulators of apoptosis and sensitize tumour cells to apoptosis. These preliminary data are worth interest when considering that this nutraceutical has been shown in vitro and in vivo to exert protective anti-tumour effect by redox status-modulating and immuno-regulatory actions. Given its lack of toxicity so far reported, such natural product might represent an effective nutritional supplement in a number of pathological conditions where a chemo-preventive strategy is planned.


REFERENCES

  1. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S62-71.

  2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5 Suppl 1): S35-50.

  3. Seeff LB. The burden of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S1-4.

  4. Nguyen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, Wright TL, Keeffe EB. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 820-824.

  5. Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF, D’Errico A, Ballardini G, Cavallari A, Grazi GL. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10: 1195-1202.

  6. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S268-276.

  7. Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S, Kobayashi N. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004; 135: 604-612.

  8. Persad R, Liu C, Wu TT, Houlihan PS, Hamilton SR, Diehl AM, Rashid A. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol 2004; 17: 861-867.

  9. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, Tamai S, Hoshino H, Inoue T, Kanisawa M. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 1994; 73: 1149-1154.

  10. Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano N. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res 1998; 4: 1475-1482.

  11. Marotta F, Rouge A, Harada M, Anzulovic H, Idéo GM, Yanaihara N, Princess G, Idéo G. Beneficial effect of a controlled Chinese herbal remedy, K-17-22, in CCl4-induced liver toxicity: an in vivo and in vitro study. Biomed Res 2001; 22: 167-174.

  12. Marotta F, Bertuccelli J, Albergati F, Harada M, Safran P, Yanaihara N, Idéo G. Ischemia-reperfusion liver injury: effect of a nutritional approach with K-17.22 on hepatic antioxidant defense system. Biomed Res 2001; 22: 221-227.

  13. Marotta F, Harada M, Goh K, Lorenzetti A, Gelosa F, Minelli E. Phytotherapeutic compound YHK exerts an inhibitory effect on early stage of experimentally-induced neoplastic liver lesions. Ann Hepatol 2006; 5: 268-272.

  14. Farhner J, Labruyere WT, Gaunitz C. Identification and functional characterization of regulatory elements of the glutamine synthesase gene from rat liver. Eur J Biochem 1993; 213: 1067-1073.

  15. Dunigan DD, Waters SB, Owen TC. Aqueous soluble tetrazolium/formazan MTS as an indicator of NADH- and NADPH-ependent dehydrogenase activity. Biotechniques 1995; 19: 640-649.

  16. Arechabala B, Coiffard C, Rivalland P, Coiffard LJ, de Roeck-Holtzhauer Y. Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release. J Appl Toxicol 1999; 19: 163-165.

  17. Lowry OH, Rosebrough NJ, Farr A, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.

  18. Shen HX, Tamai K, Satoh K, Hatayama I, Tsuchida S, Sato K. Modulation of class Pi glutathione transferase activity by sulfhydryl group modification. Arch Biochem Biophys 1991; 286: 178-182.

  19. Henning SM, Niu Y, Lee NH, Thames GD, Minutti RR, Wang H, Go VL, Heber D. Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. Am J Clin Nutr 2004; 80: 1558-1564.

  20. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Briancon S. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164: 2335-2342.

  21. Visioli F, Grande S, Bogani P, Galli C. The role of antioxidants in the Mediterranean diets: focus on cancer. Eur J Cancer Prev 2004; 13: 337-343.

  22. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood) 2004; 229: 988-995.

  23. Hayashi N. Apoptosis in liver disease. Internal Medicine 1998; 37: 191-192.

  24. Ueda S, Nakamura H, Masutani H, Sasada T, Takabayashi A, Yamaoka Y, Yodoi J. Baicalin induces apoptosis via mitochondrial pathway as prooxidant. Mol Immunol 2002; 38: 781-791.

  25. Li HL, Chen DD, Li XH, Zhang HW, Lu YQ, Ye CL, Ren XD. Changes of NF-B, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species. World J Gastroenterol 2002; 8: 431- 435.

  26. Teramoto S, Tomita T, Matsui H, Ohga E, Matsuse T, Ouchi Y. Hydrogen peroxide-induced apoptosis and necrosis in human lung fibroblasts:protective roles of glutathione. Jpn J Pharmacol 1999; 79: 33-40.

  27. Watson RW, Rotstein OD, Nathens AB, Dackiw AP, Marshall JC. Thiol-mediated redox regulation of neutrophil apoptosis. Surgery 1996; 120: 150-157.

  28. Liu J, Shen HM, Ong CN. Salvia miltiorrhiza inhibits cell growth and induces apoptosis in human hepatoma HepG2 cells. Cancer Letters 2000; 153: 85-93.

  29. Hall AG. The role of glutathione in the regulation of apoptosis. Eur J Clin Invest 1999; 29: 238-245.

  30. Simizu S, Takada M, Umezawa K, Imoto M. Requirement of caspase-3 (like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J Biol Chem 1998; 273: 26900-26907.

  31. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001 20: 1803-1815.

  32. Nishida S, Kikuichi S, Yoshioka S, Tsubaki M, Fujii Y, Matsuda H, Kubo M, Irimajiri K. Induction of apoptosis in HL-60 cells treated with medicinal herbs. Am J Chin Med 2003; 31: 551-562.

  33. Aoki K, Ishiwata S, Sakagami H, Kusama K, Katayama T. Modification of apoptosis-inducing activity of gallic acid by saliva. Anticancer Res 2001; 21: 1879-1883.

  34. Yanez J, Vicente V, Alcaraz M, Castillo J, Benavente-Garcia O, Canteras M, Teruel JA. Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer 2004; 49: 191-199.

  35. Isuzugawa K, Ogihara Y, Inoue M. Different generation of inhibitors against gallic acid-induced apoptosis produces different sensitivity to gallic acid. Biol Pharm Bull 2001; 24: 249-253.




2020     |     www.medigraphic.com